Safety & Efficacy Study of EGF Cancer Vaccine to Treat Stage IV Biomarker Positive, Wild Type EGF-R NSCLC Patients (EGF)

Phase 3 Open-label, Multicentre, Randomised Trial to Establish Safety & Efficacy of an EGF Cancer Vaccine in Inoperable, Stage IV Biomarker Positive,Wild Type EGF-R NSCLC Patients Eligible to Receive Standard Treatment and Supportive Care

The vaccine contains humanized recombinant antigen (EGF - Epithelial Growth Factor) and an adjuvant. The antibodies induced by vaccination will react with circulating EGF leading to removal of EGF from the circulation. As a result, binding to its target EGF-Receptor is prevented. Blocking of EGF-Receptor is preventing activation and stimulation of proliferation of tumour cell. A Phase 3 clinical trial on the EGF vaccine is ongoing in Cuba. The result from previous studies demonstrated positive correlation between extended survival and immune response against the vaccination in the late-stage NSCLC patients' age below 60 with improved quality of life. The purpose of this international Phase 3 trial is to determine whether the recombinant human EGF cancer vaccine is safe, immunogenic and effective in the treatment of stage IV NSCLC patients who are positive in the selective EGF biomarker and wild type EGF-Receptor compared to standard treatment and supportive care.

Study Overview

• Status: Terminated
• Conditions: Carcinoma, Non-Small-Cell Lung
• Intervention / Treatment: Biological: EGF Vaccine

• Study Type: Interventional
• Enrollment (Actual): 106
• Phase: Phase 3

Contacts and Locations

Study Locations

• Bulgaria
  • Dobrich, Bulgaria
    • "Multiprofile Hospital for Active Treatment (MHAT)-Dobrich" AD
  • Sofia, Bulgaria
    • MHAT for Women's Health-Nadezhda"OOD
• Czechia
  • Nová Ves pod Pleší, Czechia
    • Nemocnice Na Pleši s.r.o. Oddelení klinické onkologie a radioterapie
  • Pardubice, Czechia
    • Pardubická krajská nemocnice, a.s.c
  • Prague, Czechia
    • Thomayerova nemocnice
• Georgia
  • Batumi, Georgia
    • Cancer Center of Adjara
  • Tbilisi, Georgia
    • Institute of Clinical Oncology
  • Tbilisi, Georgia
    • Research Institute of Clinical Medicine
  • Tbilisi, Georgia
    • Clinic Health House
  • Tbilisi, Georgia
    • JSC, Maritime Hospital
  • Tbilisi, Georgia
    • JSC, Neo Medi
  • Tbilisi, Georgia
    • LTD, High Technology Medical Centre, University Clinic
  • Tbilisi, Georgia
    • LTD, Medulla - Chemotherapy and Immunotherapy Clinic
• Germany
  • Bochum, Germany
    • Augusta-Kranken-Anstalt Bochum
  • Hannover, Germany
    • KRH Klinikum Siloah Hannover - Oststadt
  • Heidelberg, Germany
    • Thoraxklinik Heidelberg gGmbH
  • Kiel, Germany
    • Universitatsklinikum Schleswig-Holstein (UKSH)
  • Köln, Germany
    • Kliniken der Stadt Köln GmbH
  • Leipzig, Germany
    • Universitätsklinikum Leipzig - AöR
  • München, Germany
    • LMU-München
  • Oststeinbek, Germany
    • Mühlen-Apotheke
  • Saale
    • Halle, Saale, Germany
      • Universitätsklinikum Halle (Saale) Klinik und Poliklinik fuer Innere Medizin
• Malaysia
  • Kuching, Malaysia
    • Sarawak General Hospital
  • Malacca, Malaysia
    • Mahkota Medical Center
  • Pulau Pinang, Malaysia
    • Hospital Pulau Pinang
  • Kedah
    • Alor Setar, Kedah, Malaysia
      • Hospital Sultanah Bahiyah
• Philippines
  • Davao City, Philippines
    • Davao Doctors Hospital
  • Manila, Philippines
    • Philippine General Hospital
  • Manila, Philippines
    • Cancer Research Center
  • Cebu City
    • Lahug, Cebu City, Philippines
      • Perpetual Succour Hospital
  • Manila
    • Makati, Manila, Philippines
      • Makati Medical Center
  • Metro Manila
    • Pasig, Metro Manila, Philippines
      • The Medical City
    • Quezon City, Metro Manila, Philippines
      • Lung Center of the Philippines
• Poland
  • Olsztyn, Poland
    • Samodzielny Publiczny Zespol Gruzlicy I Chorob Pluc
  • Prabuty, Poland
    • Szpital Specjalistyczny w Prabutach
• Romania
  • Craiova, Romania
    • Centrul de Oncologie "Sf. Nectarie"
  • Otopeni, Romania
    • S.C. R.T.C. Radiology Therapeutic Center S.R.L.
  • Târgu-Mureş, Romania
    • SC Oncomed SRL
• Spain
  • Barcelona, Spain
    • Hospital Universitario Quiron Dexeus
  • Madrid, Spain
    • Hospital General Universitario Gregorio Marañon
  • Madrid, Spain
    • Hospital Universitario Fundacion Jimenez Diaz
  • Madrid, Spain
    • Hospital Universitario Puerta de Hierro
  • Málaga, Spain
    • Hospital Regional Universitario de Malaga
• Thailand
  • Bangkok, Thailand
    • Bangkok Hospital Chiang Mai
  • Lampang, Thailand
    • Lampang Cancer Hospital
  • Phitsanulok, Thailand
    • Buddhachinaraj Hospital
  • Lopburi
    • Mueang, Lopburi, Thailand
      • Lopburi Cancer Hospital
  • Songkhla
    • Hat Yai, Songkhla, Thailand
      • Songklanagarind Hospital
• United Kingdom
  • Aberdeen, United Kingdom
    • Aberdeen Royal Infirmary
  • Nottingham, United Kingdom
    • Nottingham University Hospitals
  • Southampton, United Kingdom
    • University Hospital Southampton NHS Trust

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Are aged 18 or older.
2. Have serum EGF concentration >250 pg/ml determined from sample taken at screening.
3. Have wild type EGF-R sequence.
4. Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

5. Have adequate bone marrow, liver and renal function, as assessed by the Investigator. A sample taken at Screening should confirm that:

   • White blood cell (WBC) count ≥ 3000 per µL
   • Platelet count ≥ 100,000 per µL
   • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x upper limit of normal (ULN) (or ≤ 5 x ULN when liver metastases are present)
   • Total bilirubin ≤ 1.5 x ULN
   • Serum creatinine ≤ 1.5 x ULN
6. Have histologically and/or cytologically confirmed diagnosis of NSCLC, corresponding to locally and regionally advanced inoperable disease (Stage IV [as defined by the American Joint Committee on Cancer staging system- TNM 7th edition 2010]) excluding brain metastases.
7. Are eligible to receive first-line chemotherapy (without concurrent radiotherapy to thorax measurable lesions or consolidation radiotherapy).

8. Agree to use double-barrier contraception (males and females alike [if applicable]). A negative pregnancy test must be documented at Screening for females of childbearing potential.

   Note: Females of childbearing potential are defined as those women with less than 2 years after last menstruation and not surgically sterile, while post-menopausal refers to those women with at least 2 years from last menstruation.

9. Have signed a voluntary written informed consent form (ICF). Patients should be cooperative, willing and able to participate and adhere to the Protocol requirements, including their availability for the follow-up.

Exclusion Criteria:

1. Patient has no measurable disease (as defined by RECIST Criteria, version 1.1).
2. Patient has EGF-R mutation.
3. Patient has EGF serum concentration below required threshold.
4. Patient is a candidate for concurrent chemo-radiotherapy or post chemo thoracic radiotherapy.
5. Patient has a history of known or suspected central nervous system (CNS) metastases.
6. Patient has a history of primary malignancy (except resected non-melanoma skin cancer or curatively treated carcinoma in situ of the cervix), unless in complete remission and off all chemotherapy and/or radiotherapy for that disease for a minimum of 5 years. Any palliative radiotherapy to alleviate pain in bone metastases is permitted.
7. Patient is taking immunosuppressant drugs such as azathioprine, tacrolimus, cyclosporine, etc. Use is not permitted within 1 month before Screening.
8. Patient is taking any other immunotherapy.
9. Patient has primary or secondary immunodeficiencies (e.g. documented Human Immunodeficiency Virus [HIV]).
10. Patient has autoimmune disease.
11. Patient has undergone splenectomy.
12. Patient is taking oral, intramuscular or intravenous corticosteroids. Use is not permitted within 1 month before Screening. Inhaled corticosteroids to treat respiratory insufficiency (e.g. chronic obstructive pulmonary disease [COPD]), or topical steroids are permitted.
13. Patient has neurotoxicity (Grade ≥2).
14. Patient has diarrhoea (Grade ≥2).
15. Patient has received other vaccines (with the exception of the influenza vaccine), within 1 month before Screening.
16. Patient has a history of any severe or life-threatening hypersensitivity reaction.
17. Patient has an unstable systemic disease (including active infection, uncontrolled hypertension, unstable angina, congestive heart failure, myocardial infarction within the previous year, serious cardiac arrhythmia requiring medication, hepatic, renal and metabolic disease).
18. Patient has recent history (within 6 months before Screening) of chronic alcohol or drug abuse which may compromise the patient's safety or ability to participate in study activities.
19. Patient has a history of psychiatric disorder that prevents patients from providing informed consent or following Protocol instructions.
20. Patient is currently enrolled in an investigational device or drug trial, or <1 month since completing an investigational device or drug trial.
21. Female patients who are pregnant or lactating.
22. Patient has any other factor that in the opinion of the Investigator (or designee) would make the patient unsafe or unsuitable for the study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: RANDOMIZED
• Interventional Model: PARALLEL
• Masking: NONE

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: EGF Vaccine; Patients in this arm will receive a low dose of cyclophosphamide and the recombinant human rEGF-P64K/Montanide ISA 51	Biological: EGF Vaccine; 1.2mL of conjugate-adjuvant mix injection at four sites during the Post First-Line Chemotherapy. Reduced dose of injection at two sites during the Pre-Progression Phase.; Other Names: Cyclophosphamide and the recombinant human rEGF-P64K/Montanide ISA 51
NO_INTERVENTION: Best Supportive Care; Patients in this arm will receive best supportive care

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Overall Survival (OS)	To assess overall survival (OS) of an EGF cancer vaccine in inoperable, stage IV biomarker positive, wild type EGF-R, NSCLC patients compared to the control group receiving best treatment and supportive care. OS is defined as the time from randomisation to death due to any cause.	Each patient will be followed till death occurs within study time frame of 3 years

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Safety of EGF Cancer Vaccine as assessed by Adverse Events (AEs)	To assess the frequency and number of patients develop AEs, related AEs, serious AEs (SAEs) and AEs leading to withdrawal or death	Each patient will be followed till death occurs within study time frame of 3 years
Progression-Free Survival (PFS)	Progression parameters include radiological or clinical progression, withdrawal due to progression, and death due to any cause.	Each patient will be followed till objective tumour progression or death (whichever occurs first) within time frame of study of 3 years
Survival Rate	To assess the percentage of patients that are alive at 12 months and 24 months in EGF cancer vaccine study group compared to control group.	Each patient will be followed at 12 and 24 months after randomization
Time to Progression (TTP)	To assess Time to Progression (TTP) from the time of randomisation to first documented disease progression of EGF cancer vaccine study group patients compared to control group.	Each patient will be followed till observed tumour progression within study time frame of 3 years
Response Rate (RECIST criteria)	To assess the percentage of patients with a complete response (CR) or partial response (PR) as per Response Evaluation Criteria In Solid Tumors (RECIST) criteria Version 1.1.	Each patients will be followed till death occurs within study time frame of 3 years
Safety of EGF Cancer Vaccine by Laboratory Assessment	To assess haematology, biochemistry and urinalysis parameters	Each patients will be followed till death occurs within study time frame of 3 years
Safety of EGF Cancer Vaccine assessed by Vital Signs	To assess systolic and diastolic blood pressure, body temperature and pulse rate	Each patients will be followed till death occurs within study time frame of 3 years
Safety of EGF Cancer Vaccine as assessed by Physical Examination	To assess eyes, neurological and cardiovascular systems, lungs, abdomen, and any other areas with signs and symptoms of disease, and of the head, neck, ears, nose, mouth, throat, thyroid, lymph nodes and extremities	Each patient will be followed till death occurs within study time frame of 3 years
Quality of Life (QoL)	To assess the general physical health of patients with a 36-item, short-form health survey until disease progression	Each patient will be followed till death occurs within study time frame of 3 years

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Pharmacodynamics (PD) of EGF Cancer Vaccine assessed by Immune Responses	To assess the serum EGF concentration and anti-EGF antibody titers with response before and after to the study treatment	Each patients will be followed till death within study time frame of 3 years
Efficacy assessed by KRAS and ALK rearrangements	For the analysis of oncogenes Kirsten rat sarcoma (KRAS) and anaplastic lymphoma kinase (ALK), a formalin-fixed, paraffin embedded (FFPE) sample of the biopsy tumour tissue, ideally taken from biopsy obtained at disease diagnosis will be prepared and shipped for central analysis	At time of screening

Collaborators and Investigators

• Sponsor: Bioven Europe
• Investigators: Principal Investigator: Libor Havel, Dr., Thomayerova nemocnice, Czech Republic

Study record dates

Study Major Dates

• Study Start (ACTUAL): May 1, 2015
• Primary Completion (ACTUAL): May 1, 2019
• Study Completion (ACTUAL): September 6, 2019

Study Registration Dates

• First Submitted: July 7, 2014
• First Submitted That Met QC Criteria: July 9, 2014
• First Posted (ESTIMATE): July 11, 2014

Study Record Updates

• Last Update Posted (ACTUAL): September 10, 2019
• Last Update Submitted That Met QC Criteria: September 9, 2019
• Last Verified: September 1, 2019

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Respiratory Tract Diseases; Neoplasms; Lung Diseases; Neoplasms by Site; Respiratory Tract Neoplasms; Thoracic Neoplasms; Carcinoma, Bronchogenic; Bronchial Neoplasms; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Antirheumatic Agents; Antineoplastic Agents; Immunosuppressive Agents; Immunologic Factors; Antineoplastic Agents, Alkylating; Alkylating Agents; Myeloablative Agonists; Cyclophosphamide
• Other Study ID Numbers: BV-NSCLC-002; 2013-005335-25 (EUDRACT_NUMBER)